Tag Archives: Medicare

State Surprises as Obamacare Starts Up

by Tom Norton This past week or so, with Obamacare’s start up less than a year away, we have been treated to several entertaining vignettes as the nation’s governors begin to wrestle with the realities of the new healthcare law.  
Posted in Guest Blog, healthcare, leadership, Legal, Strategy | Also tagged , , , , , , , | Leave a comment

Pharma Pricing Top Target for Medicare Cutbacks

In the dog-eat-dog world of federal deficit reduction, there seems to be one health-related spending cut with broad bi-partisan support:  require drug companies to give the federal government “a better deal on medications for low-income people on Medicare.” Nearly 70% of respondents back this strategy, according to a survey sponsored by the Kaiser Family Foundation […]
Posted in healthcare, pricing | Also tagged , , , , , , | 2 Comments

With the Election Decided, It's Full Speed Ahead on ObamaCare

by Tom Norton With the Presidential election decided and President Obama the clear winner, it’s time for Pharma to get down to business on the implementation of ObamaCare.  Here are some of the key actions to anticipate between now and January 1, 2013.
Posted in FDA, healthcare, Legal, Regulatory, Strategy | Also tagged , , , , , | 3 Comments

Sequestration: What Does it Mean for Pharma?

You may have read horror stories about the looming Sequestration Act, but what exactly is it? And what does it mean for US pharma? Tom Norton reports. Lurking in the shadows of the US General Elections is something called The Sequestration Transparency Act of 2011. Of late, you may have read the occasional article that […]
Posted in Guest Blog, Regulatory | Also tagged , , , , , | 2 Comments

Budget policies jeopardize FDA funding, user fees

Budget policies jeopardize FDA funding, user fees Even though Congress authorized both existing and new user fees for the Food and Drug Administration several months ago through the FDA Safety & Innovation Act (FDASIA), efforts to cut the federal deficit raises questions about how those fees will be collected and used in the coming year. […]
Posted in FDA, Guest Blog, Regulatory | Also tagged , , , , , | Leave a comment
  • Categories

  • Meta